Advanced Materials for Cell and Gene Therapy Manufacturing

Higher quality cell-based therapeutics

StemBond Technologies is redefining the potential of cell culture with advanced materials science.


By providing precise, mechanically tuned cell culture environments with our proprietary platform technology, we aim to develop  higher-quality cell products.

About Us

Cambridge University Spin-Out

StemBond Technologies aims to leverage advances made in controlling cell fate and function at the Stem Cell Institute for our partners and future cell products. We are based in the Stem Cell Institute, Cambridge, UK.

Partnerships

The StemBond platform can be mechanically personalised to support an array of vital cell types. We are looking for partners in need of defined cell culture substrates for improved cell function.

Technology: StemBond Hydrogels

Our proprietary hydrogel tissue culture platform delivers the benefits of 3D culture with 2D scalability. With the potential to be GMP compliant and transplantable, StemBond has the capacity to redefine the therapeutic potential of ex vivo cell culture.

Higher-quality cell products

Our platform modulates cell signalling through precise mechanical control of cell culture environments. This is an immensely powerful tool for preserving and enhancing cell function outside of the body.

Our Team

Dr Andrew C. Hodgson

Co-Founder CEO, Director

Prof. Kevin Chalut

Co-Founder and Scientific Advisor, Director

Dr Agata Nyga

Head of R&D

Board of Directors

Dr Miguel Forte

Executive Chair

Dr Jason Mellad

Director and Investor

Dr Karin Schmitt

Non-Executive Director

Dr Robert Preti

Non-Executive Director

Upcoming Events:

News

Collaborations

Contact us to discuss how our platforms could work for you.


We can design pilot studies through to integration and novel applications.


Key Publications

Our cell culture platform has been adopted by leading research groups


Investors, Partners and Affiliations

Share by: